208 related articles for article (PubMed ID: 23393051)
1. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.
Jackman RP; Deng X; Bolgiano D; Lebedeva M; Heitman JW; Busch MP; Slichter SJ; Norris PJ
Blood; 2013 Apr; 121(16):3261-6; quiz 3299. PubMed ID: 23393051
[TBL] [Abstract][Full Text] [Related]
2. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
[TBL] [Abstract][Full Text] [Related]
3. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
[TBL] [Abstract][Full Text] [Related]
6. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
[TBL] [Abstract][Full Text] [Related]
7. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
8. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
9. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
Pappalardo PA; Secord AR; Quitevis P; Haimowitz MD; Goldfinger D
Transfusion; 2001 Aug; 41(8):984-7. PubMed ID: 11493728
[TBL] [Abstract][Full Text] [Related]
10. Use of HLA- and HPA--matched platelets in alloimmunized patients.
Kekomäki R
Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
[TBL] [Abstract][Full Text] [Related]
11. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
Brubaker DB; Romine M
Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
[TBL] [Abstract][Full Text] [Related]
12. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
13. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
14. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients.
Schnaidt M; Northoff H; Wernet D
Transfus Med; 1996 Jun; 6(2):111-4. PubMed ID: 8809957
[TBL] [Abstract][Full Text] [Related]
15. Platelet alloantibodies in transfused patients.
Kiefel V; König C; Kroll H; Santoso S
Transfusion; 2001 Jun; 41(6):766-70. PubMed ID: 11399817
[TBL] [Abstract][Full Text] [Related]
16. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
[TBL] [Abstract][Full Text] [Related]
17. [Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients].
Xia WJ; Ye X; Deng J; Chen YK; Xu XZ; Ding HQ; Luo GP; Fu YS
Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):594-8. PubMed ID: 21122318
[TBL] [Abstract][Full Text] [Related]
18. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
[TBL] [Abstract][Full Text] [Related]
19. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
Figueiredo C; Blaszczyk R
J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
[TBL] [Abstract][Full Text] [Related]
20. The challenge of platelet alloimmunization: management and prevention.
Kickler TS
Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]